CHRS dividend history

REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS) today announced that it has initiated the process to market and sell the remaining assets associated with the Company’s former biosimilars business (the "Legacy BioSim Assets"). The Company has retained Oppenheimer & Co. Inc. ("Oppenheimer") to serve as its financial advisor in connection with the sale. Parties interested in the opportunity should direct inquiries to the Oppenheimer contacts listed below. "We are pleased to be working with a bank of Oppenheimer’s caliber to market our legacy biosimilars assets," said Denny Lanfear, President and Chief Executive Officer of Coherus. "We are confide

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS) ("Coherus", "Coherus Oncology" or the "Company") today announced a special dividend of contingent value rights (each, a "CVR" and collectively, the "CVRs"), which will be distributed on a pro rata basis to stockholders of record of the Company’s common stock as of 5:00 p.m., New York City time, on September 30, 2026 (the "Record Date"). The distribution date for the CVRs (the "Distribution Date")